Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity

BACKGROUND: To estimate real-world outcomes in East Asian populations, we conducted a nationwide retrospective analysis of the efficacy and safety of lenalidomide for del(5q) myelodysplastic syndrome (MDS) patients with transfusion-dependent anemia in Korea. METHODS: Patients aged ≥19 years who had...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Junshik, Lee, Yoo Jin, Bae, Sung Hwa, Yi, Jun Ho, Park, Sungwoo, Chang, Myung Hee, Park, Young Hoon, Hyun, Shin Young, Chung, Joo-Seop, Jang, Ji Eun, Jung, Joo Young, Jeon, So-Yeon, Song, Seo-Young, Kim, Hawk, Kim, Dae Sik, Kim, Sung-Hyun, Kim, Min Kyoung, Han, Sang Hoon, Park, Seonyang, Kim, Yoo-Jin, Lee, Je-Hwan, AML, on behalf of the, Hematology, MDS Working Party of the Korean Society of
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246035/
https://www.ncbi.nlm.nih.gov/pubmed/34187943
http://dx.doi.org/10.5045/br.2021.2021086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246035/
https://www.ncbi.nlm.nih.gov/pubmed/34187943
http://dx.doi.org/10.5045/br.2021.2021086

Ejemplares similares